ArticleBMC pregnancy and childbirth2026
Hi-C technology for detection of chromosomal rearrangements in families with adverse pregnancy outcomes: a preliminary exploratory study.
Article in BMC pregnancy and childbirth, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Chromosomal abnormalities are a leading cause of adverse pregnancy outcomes. Conventional methods such as karyotyping and chromosomal microarray analysis (CMA) have limited ability to detect cryptic, mosaic, or repeat-region structural variants. This preliminary exploratory study evaluated the feasibility and potential utility of Hi-C in comparison with karyotyping, CMA, optical genome mapping (OGM), and structural variant sequencing (SV-seq) in two families with unexplained or incompletely characterized recurrent adverse pregnancy outcomes. In Family 1, CMA and recurrent abnormal NIPS results suggested maternal mosaic copy number changes, and high depth karyotyping, SV-seq, and Hi-C supported a mosaic unbalanced translocation involving chromosomes 9 and 18; OGM detected the copy number changes but did not resolve the underlying cryptic rearrangement structure. In Family 2, Hi-C, together with OGM and SV-seq, refined the candidate breakpoint regions of a balanced translocation initially detected by karyotyping, and supported transmission of the same rearrangement to the daughter. These findings suggest that Hi-C may serve as a valuable complementary diagnostic tool for identifying cryptic balanced or mosaic chromosomal rearrangements in selected families with unexplained or incompletely characterized recurrent adverse pregnancy outcomes. Larger sample prospective studies are still required to verify its general clinical application in the future.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.